Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
about
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsMechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a DerivativeWnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.Expression and activity of multidrug resistance proteins in mature endothelial cells and their precursors: A challenging correlation.Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?Membrane microparticles: shedding new light into cancer cell communication.Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells.11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway.[Molecular tumour therapy].
P2860
Q26849792-1ED90FF6-1C05-4537-9313-D31572EFBA75Q33600323-C9C1AE87-12B8-41AA-9C59-002D2B1BB7BBQ34348134-19CCFB06-EFA1-470C-8928-D6974E5156E2Q35051303-98B6DF68-80DA-4758-8B38-56836680D9B3Q35991845-57F5540F-6D95-488B-8ABC-D46C1D910B9EQ36284267-13CC2883-86A3-42F8-B9B4-4E383C3D6B92Q38011895-EBEEC48B-766B-4303-A582-2E6A91118B47Q38082728-FF650FD1-7319-4C30-8A75-D33E4B619694Q38144200-08A6D3E0-F0C8-4D65-A94A-8CF621A99A85Q38569109-6BB53479-5F05-4AF0-A410-3A3395DB1E23Q38697712-B98E9A34-0B8F-43FC-A7FD-B05C59D80565Q38752210-310E9417-5E11-4451-AE04-50198CBE297FQ39121828-7531796E-7A2E-4B9B-B4E2-4F3D4F77C92BQ39404062-4EF7F92A-1D80-4F06-B7C7-BA19259471D0Q39638448-A1C2B5BD-8DB4-402C-BD51-F9B7ADAA0FBCQ41842515-56DB7392-F12C-4F0A-9A5F-6F3471795449Q47216949-BDA44E48-E522-480B-B32E-7148C3816B1AQ49875852-77AE5716-73E1-4D46-BEF9-779BC9B6E84FQ53808609-E257FCD3-444B-4EA6-9A29-4AFD91C1B5BA
P2860
Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Variation of MDR proteins expr ...... and evolution of CML patients.
@en
Variation of MDR proteins expr ...... and evolution of CML patients.
@nl
type
label
Variation of MDR proteins expr ...... and evolution of CML patients.
@en
Variation of MDR proteins expr ...... and evolution of CML patients.
@nl
prefLabel
Variation of MDR proteins expr ...... and evolution of CML patients.
@en
Variation of MDR proteins expr ...... and evolution of CML patients.
@nl
P2093
P2860
P356
P1476
Variation of MDR proteins expr ...... and evolution of CML patients.
@en
P2093
Arthur Moellmann-Coelho
Claudete E Klumb
Flavia C Vasconcelos
Karina L Silva
Luiz Felipe R Silva
Paloma Silva de Souza
Raquel Ciuvalschi Maia
P2860
P304
P356
10.1002/CYTO.B.20580
P577
2010-12-02T00:00:00Z